Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome

Table 2 Duration, adverse effects, adherence and drug withdrawal of colchicine treatment

Study code^a	Duration of colchicine treatment (and treatment start post heart surgery in PPS)	Adverse effects (AE) [%], non-adherence (NA) [%] and drug withdrawal (DW) [%]
01	1 month (start at 3rd postoperative day)	SAE: 0% AE: 14.1% GI: 11.7% AR: 0.6% RF: 1.2% PR: 0.6% NA: 10.4% DW: n.r.
02	6 months	SAE: 0% AE: 7% GI: 7% NA: 0% DW: n.r.
03	3 months	SAE: 0% AE: 8.3% GI: 8.3% NA: 0% DW: n.r.
04	1 month (start at 3rd postoperative day)	SAE: 0% AE: 8.9% GI: 8.9% NA: n.r. DW: 11.7% DW-AE: 8.9% DW-OR: 2.8%
05	6 months	SAE: 0% AE: 11.7% GI: 7% NA: n.r. DW: 8% DW-AE: 7% DW-OR: 1%
06	3 months	SAE: 0% AE: 11.7% GI: 7% HT: 1.7% AP: 0.8% NA: < 5% DW: 11.7% DW-AE: 11.7% DW-OR: 0%
07	1 month (start at 48–72 h before heart surgery)	SAE: 0% AE: 20% GI: 14.4% HT: 0.6% NA: < 5% DW: 21.7% DW-AE: 20% DW-OR: 1.7%
08	6 months	SAE: 0% AE: 11.7% GI: 7.5% HT: 2.5% MT: 0.8% AP: 0.8% NA: < 5% DW: 6.7% DW-AE: 6.7% DW-OR: 0%
09	14 days (start at 7–30 days after heart surgery)	SAE: 0% AE: 10.2% GI: 9.2% LP: 1% NA: 9.2% DW: 10.2% DW-AE: 10.2%
10	14 days (start at 3 weeks after heart surgery)	SAE: 0% AE: n.r. NA: n.r. DW: n.r.

^astudy code of the publications included in the meta-analysis
n.r. value not referred in the publication, SAE serious adverse effects, AE adverse effects, GI gastrointestinal intolerance, AR allergic reaction, RF renal failure, PR pancreatitis, HT hepatotoxicity, AP alopecia, LP leucopenia, NA non-adherence, DW drug-withdrawal, DW-AE drug-withdrawal due to adverse effects, DW-OR drug-withdrawal due to other reasons (e.g. patient or medical decision)

ISSN: 1471-2261